Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.69 |
| ▸ | IKZF3 | Q9UKT9 | 12/20 | 0.69 |
| ▸ | TNF | P01375 | 7/20 | 0.59 |
| ▸ | IL1B | P01584 | 4/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30241767 | 1.00 | CRBN (0.69) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL30262767 | 0.99 | CRBN (0.68) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL22962692 | 0.99 | CRBN (0.68) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL30262829 | 0.99 | CRBN (0.68) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL30262761 | 0.99 | CRBN (0.68) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL21741820 | 0.99 | CRBN (0.68) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL22959686 | 0.99 | CRBN (0.68) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL30262873 | 0.99 | CRBN (0.68) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL29223489 | 0.99 | CRBN (0.68) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL24123477 | 0.97 | CRBN (0.71) | CRBNIKZF3TNFIL1BDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115666575-A | Compound and use thereof | 福宏治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| WO-2021023233-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | 上海科技大学 | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CRBN 179/4885IKZF3 1442/4885TNF 4869/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | CRBN 3528/4885IKZF3 2946/4885TNF 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.